Supernus Pharmaceuticals | SUPN - Des Atouts





Des Atouts Changement Date
Abbott USD 110.43B 23.72B 2026-03
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
Aurora Cannabis CAD 775.29M 18.43M 2025-12
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Canopy Growth CAD 1.11B 36.35M 2025-12
Cara Therapeutics USD 39.02M 4.73M 2025-09
Corcept Therapeutics USD 814.88M 21.77M 2026-03
Eisai JPY 1.49T 48.22B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Novo Nordisk DKK 542.9B 30.61B 2025-12
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Xeris Pharmaceuticals USD 383.53M 13.34M 2025-12